Could hormonal contraceptives increase risk of gestational diabetes?
A recent Centers for Disease Control and Prevention (CDC) study of data from a single state suggests that there may be a connection between use of hormonal contraceptives prior to pregnancy and increased risk of developing gestational diabetes (GDM).
A recent Centers for Disease Control and Prevention (CDC) study of data from a single state suggests that there may be a connection between use of hormonal contraceptives prior to pregnancy and increased risk of developing gestational diabetes (GDM). The authors caution, however, that their findings suggest an underlying causal mechanism rather than establishing a causal relationship and are not generalizable to pregnant women with our outcomes or in other states.
The analysis, using a logistic regression model to determine adjusted odds of GDM following exposure to hormonal contraceptives, reflects data from 2741 women collected in 2007 and 2008 by the Missouri Pregnancy Risk Assessment Monitoring System (PRAMS). Missouri is one of 40 states and New York City that administer the ongoing, population-based survey, which is designed to identify and monitor select maternal experiences, attitudes, and behaviors that occur before, during, and shortly after pregnancy in women who deliver a live infant.
Of the women who completed the Missouri PRAMS survey, 8.3% were given a GDM diagnosis in their most recent pregnancy. Hormonal methods were the contraceptives most commonly used by respondents (17.9%), followed by barrier methods (17.2%), fertility awareness/rhythm method (6.8%), and other (2.3%). Overall, 56% of women surveyed said they used no contraception.
When compared with women who used no contraception, those who used hormonal contraceptives had higher odds of developing GDM (adjusted odds ratio [AOR] = 1.43; 95% confidence interval [CI], 1.32-1.55). However, a protective effect for GDM was noted for women using barrier methods of contraception (AOR = 0.79; 95% CI, 0.72 – 0.86) versus no contraception and for those whose pregnancy was unintended versus intended (AOR = 0.39; 95% CI, 0.37-0.42).
Investigators concluded that there might be a relationship between the type of contraception used and GDM. Noting that this is the first study to evaluate the relationship between type of contraception used before pregnancy and risk of GME, they recommended further research into the possible correlation.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More
